# Yingjie Zhang

List of Publications by Year
in descending order



| 92 | 2,009 | 236612 | 288905 |
|---|---|---|---|
| papers | citations | 25 h-index | 40 g-index |

| 95 | 95 | 95 | 2624 |
|---|---|---|---|
| all docs | docs citations | times ranked | citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | A novel small molecular NLRP3 inflammasome inhibitor alleviates neuroinflammatory response following traumatic brain injury. Journal of Neuroinflammation, 2019, 16, 81. | 3.1 | 127 |
| 2 | Development of Tetrahydroisoquinoline-Based Hydroxamic Acid Derivatives: Potent Histone Deacetylase Inhibitors with Marked in Vitro and in Vivo Antitumor Activities. Journal of Medicinal Chemistry, 2011, 54, 2823-2838. | 2.9 | 85 |
| 3 | Histone deacetylase (HDAC) inhibitors in cancer: a patent review (2017-present). Expert Opinion on Therapeutic Patents, 2020, 30, 263-274. | 2.4 | 81 |
| 4 | Discovery of Novel Pazopanib-Based HDAC and VEGFR Dual Inhibitors Targeting Cancer Epigenetics and Angiogenesis Simultaneously. Journal of Medicinal Chemistry, 2018, 61, 5304-5322. | 2.9 | 78 |
| 5 | Design, Synthesis, and Antitumor Evaluation of Novel Histone Deacetylase Inhibitors Equipped with a Phenylsulfonylfuroxan Module as a Nitric Oxide Donor. Journal of Medicinal Chemistry, 2015, 58, 4325-4338. | 2.9 | 76 |
| 6 | Discovery of the First N-Hydroxycinnamamide-Based Histone Deacetylase 1/3 Dual Inhibitors with Potent Oral Antitumor Activity. Journal of Medicinal Chemistry, 2014, 57, 3324-3341. | 2.9 | 71 |
| 7 | JAK/STAT Signal Transduction: Promising Attractive Targets for Immune, Inflammatory and Hematopoietic Diseases. Current Drug Targets, 2018, 19, 487-500. | 1.0 | 71 |
| 8 | Discovery of N-Substituted Oseltamivir Derivatives as Potent and Selective Inhibitors of H5N1 Influenza Neuraminidase. Journal of Medicinal Chemistry, 2014, 57, 8445-8458. | 2.9 | 65 |
| 9 | Class I HDAC Inhibitors Display Different Antitumor Mechanism in Leukemia and Prostatic Cancer Cells Depending on Their p53 Status. Journal of Medicinal Chemistry, 2018, 61, 2589-2603. | 2.9 | 60 |
| 10 | Discovery of Novel Janus Kinase (JAK) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Hematological Malignancies. Journal of Medicinal Chemistry, 2019, 62, 3898-3923. | 2.9 | 60 |
| 11 | Discovery of a Tetrahydroisoquinoline-Based Hydroxamic Acid Derivative (ZYJ-34c) as Histone Deacetylase Inhibitor with Potent Oral Antitumor Activities. Journal of Medicinal Chemistry, 2011, 54, 5532-5539. | 2.9 | 58 |
| 12 | Design, synthesis and preliminary activity assay of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid derivatives as novel Histone deacetylases (HDACs) inhibitors. Bioorganic and Medicinal Chemistry, 2010, 18, 1761-1772. | 1.4 | 56 |
| 13 | The Structure and Function of Histone Deacetylases: The Target for Anti-cancer Therapy. Current Medicinal Chemistry, 2008, 15, 2840-2849. | 1.2 | 50 |
| 14 | Progress on Kinesin Spindle Protein Inhibitors as Anti-Cancer Agents. Anti-Cancer Agents in Medicinal Chemistry, 2008, 8, 698-704. | 0.9 | 45 |
| 15 | Development of N-Hydroxycinnamamide-Based Histone Deacetylase Inhibitors with an Indole-Containing Cap Group. ACS Medicinal Chemistry Letters, 2013, 4, 235-238. | 1.3 | 43 |
| 16 | Discovery of Novel Pyrrolo[2,3-d]pyrimidine-based Derivatives as Potent JAK/HDAC Dual Inhibitors for the Treatment of Refractory Solid Tumors. Journal of Medicinal Chemistry, 2022, 65, 1243-1264. | 2.9 | 42 |
| 17 | VEGF Signal System: The Application of Antiangiogenesis. Current Medicinal Chemistry, 2014, 21, 894-910. | 1.2 | 39 |
| 18 | Design of Hydrazide-Bearing HDACIs Based on Panobinostat and Their p53 and FLT3-ITD Dependency in Antileukemia Activity. Journal of Medicinal Chemistry, 2020, 63, 5501-5525. | 2.9 | 37 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Preclinical and Clinical Studies of Chidamide (CS055/HBI-8000), An Orally Available Subtype-selective HDAC Inhibitor for Cancer Therapy. Anti-Cancer Agents in Medicinal Chemistry, 2017, 17, 802-812. | 0.9 | 37 |
| 20 | Progress of HDAC Inhibitor Panobinostat in the Treatment of Cancer. Current Drug Targets, 2014, 15, 622-634. | 1.0 | 31 |
| 21 | Design, Synthesis and Biological Evaluation of Novel Osimertinib-Based HDAC and EGFR Dual Inhibitors. Molecules, 2019, 24, 2407. | 1.7 | 30 |
| 22 | Selective HDAC inhibitors with potent oral activity against leukemia and colorectal cancer: Design, structure-activity relationship and anti-tumor activity study. European Journal of Medicinal Chemistry, 2017, 134, 185-206. | 2.6 | 28 |
| 23 | Design, Synthesis, and Antitumor Evaluation of 4-Amino-(1H)-pyrazole Derivatives as JAKs Inhibitors. ACS Medicinal Chemistry Letters, 2016, 7, 950-955. | 1.3 | 27 |
| 24 | Discovery of meta-sulfamoyl N-hydroxybenzamides as HDAC8 selective inhibitors. European Journal of Medicinal Chemistry, 2018, 150, 282-291. | 2.6 | 27 |
| 25 | Non-platelet-derived CXCL4 differentially regulates cytotoxic and regulatory T cells through CXCR3 to suppress the immune response to colon cancer. Cancer Letters, 2019, 443, 1-12. | 3.2 | 27 |
| 26 | Synthesis and biological evaluation of N-(4-hydroxy-3-mercaptonaphthalen-1-yl)amides as inhibitors of angiogenesis and tumor growth. European Journal of Medicinal Chemistry, 2013, 64, 377-388. | 2.6 | 24 |
| 27 | Design, synthesis and anti-tumor activity study of novel histone deacetylase inhibitors containing isatin-based caps and o -phenylenediamine-based zinc binding groups. Bioorganic and Medicinal Chemistry, 2017, 25, 2981-2994. | 1.4 | 23 |
| 28 | Discovery of a fluorescent probe with HDAC6 selective inhibition. European Journal of Medicinal Chemistry, 2017, 141, 596-602. | 2.6 | 23 |
| 29 | Design, synthesis and primary activity assay of tripeptidomimetics as histone deacetylase inhibitors with linear linker and branched cap group. European Journal of Medicinal Chemistry, 2011, 46, 5387-5397. | 2.6 | 22 |
| 30 | Potent Hydrazide-Based HDAC Inhibitors with a Superior Pharmacokinetic Profile for Efficient Treatment of Acute Myeloid Leukemia In Vivo. Journal of Medicinal Chemistry, 2022, 65, 285-302. | 2.9 | 22 |
| 31 | Discovery of BC-01, a novel mutual prodrug (hybrid drug) of ubenimex and fluorouracil as anticancer agent. European Journal of Medicinal Chemistry, 2016, 121, 649-657. | 2.6 | 21 |
| 32 | Development of N -hydroxycinnamamide-based HDAC inhibitors with improved HDAC inhibitory activity and in vitro antitumor activity. Bioorganic and Medicinal Chemistry, 2017, 25, 2666-2675. | 1.4 | 20 |
| 33 | Nitric oxide donor hybrid compounds as promising anticancer agents. Drug Discoveries and Therapeutics, 2016, 10, 276-284. | 0.6 | 19 |
| 34 | Progress on kinesin spindle protein inhibitors as anti-cancer agents. Anti-Cancer Agents in Medicinal Chemistry, 2008, 8, 698-704. | 0.9 | 19 |
| 35 | Design, synthesis and preliminary evaluation of Î±-sulfonyl Î³-(glycinyl-amino)proline peptidomimetics as matrix metalloproteinase inhibitors. Bioorganic and Medicinal Chemistry, 2014, 22, 3055-3064. | 1.4 | 18 |
| 36 | Synthesis and biological evaluation of novel histone deacetylases inhibitors with nitric oxide releasing activity. Bioorganic and Medicinal Chemistry, 2015, 23, 4481-4488. | 1.4 | 18 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Anlotinib Combined With Chemoradiotherapy Exhibits Significant Therapeutic Efficacy in Esophageal Squamous Cell Carcinoma. Frontiers in Oncology, 2020, 10, 995. | 1.3 | 18 |
| 38 | Synthesis and biological characterization of ubenimex-fluorouracil conjugates for anti-cancer therapy. European Journal of Medicinal Chemistry, 2018, 143, 334-347. | 2.6 | 17 |
| 39 | Design, synthesis and biological evaluation of tyrosine-based hydroxamic acid analogs as novel histone deacetylases (HDACs) inhibitors. Bioorganic and Medicinal Chemistry, 2011, 19, 4437-4444. | 1.4 | 16 |
| 40 | Discovery of N-(3-((7H-purin-6-yl)thio)-4-hydroxynaphthalen-1-yl)-sulfonamide derivatives as novel protein kinase and angiogenesis inhibitors for the treatment of cancer: Synthesis and biological evaluation. Part III. Bioorganic and Medicinal Chemistry, 2014, 22, 1487-1495. | 1.4 | 16 |
| 41 | Development of a Bestatin-SAHA Hybrid with Dual Inhibitory Activity against APN and HDAC. Molecules, 2020, 25, 4991. | 1.7 | 16 |
| 42 | Development of selective HDAC6 inhibitors with in vitro and in vivo anti-multiple myeloma activity. Bioorganic Chemistry, 2021, 116, 105278. | 2.0 | 16 |
| 43 | Enhanced anticancer activity of 5-FU in combination with Bestatin: Evidence in human tumor-derived cell lines and an H22 tumor-bearing mouse. Drug Discoveries and Therapeutics, 2015, 9, 45-52. | 0.6 | 15 |
| 44 | Importinâ€4 functions as a driving force in human primary gastric cancer. Journal of Cellular Biochemistry, 2019, 120, 12638-12646. | 1.2 | 15 |
| 45 | Development of 3-hydroxycinnamamide-based HDAC inhibitors with potent inÂvitro and inÂvivo anti-tumor activity. European Journal of Medicinal Chemistry, 2015, 89, 628-637. | 2.6 | 14 |
| 46 | Discovery of a novel chimeric ubenimexâ€“gemcitabine with potent oral antitumor activity. Bioorganic and Medicinal Chemistry, 2016, 24, 5787-5795. | 1.4 | 14 |
| 47 | Novel leucine ureido derivatives as aminopeptidase N inhibitors. Design, synthesis and activity evaluation. European Journal of Medicinal Chemistry, 2016, 108, 21-27. | 2.6 | 13 |
| 48 | Discovery of 4-amino-2-(thio)phenol derivatives as novel protein kinase and angiogenesis inhibitors for the treatment of cancer: Synthesis and biological evaluation. Part II. European Journal of Medicinal Chemistry, 2013, 69, 191-200. | 2.6 | 12 |
| 49 | Development of N-hydroxybenzamide derivatives with indole-containing cap group as histone deacetylases inhibitors. Bioorganic and Medicinal Chemistry, 2015, 23, 6258-6270. | 1.4 | 12 |
| 50 | A comparison of the location in membranes of curcumin and curcumin-derived bivalent compounds with potential neuroprotective capacity for Alzheimerâ€™s disease. Colloids and Surfaces B: Biointerfaces, 2021, 199, 111525. | 2.5 | 12 |
| 51 | Progress of CDK4/6 Inhibitor Palbociclib in the Treatment of Cancer. Anti-Cancer Agents in Medicinal Chemistry, 2019, 18, 1241-1251. | 0.9 | 12 |
| 52 | Design, Synthesis, and Biological Evaluation of Pyrazolineâ€Based Hydroxamic Acid Derivatives as Aminopeptidaseâ€…N (APN) Inhibitors. ChemMedChem, 2018, 13, 431-436. | 1.6 | 11 |
| 53 | External-beam partial breast irradiation in a supine versus prone position after breast-conserving surgery for Chinese breast cancer patients. Scientific Reports, 2018, 8, 15354. | 1.6 | 11 |
| 54 | Histone deacetylase inhibitors merged with protein tyrosine kinase inhibitors. Drug Discoveries and Therapeutics, 2015, 9, 147-155. | 0.6 | 10 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Isoform-selective histone deacetylase inhibitors: the trend and promise of disease treatment. Epigenomics, 2015, 7, 5-7. | 1.0 | 10 |
| 56 | Novel leucine ureido derivatives as aminopeptidase N inhibitors using click chemistry. Bioorganic and Medicinal Chemistry, 2018, 26, 3145-3157. | 1.4 | 10 |
| 57 | Discovery of a Novel Hybrid of Vorinostat and Riluzole as a Potent Antitumor Agent. Frontiers in Cell and Developmental Biology, 2020, 8, 454. | 1.8 | 10 |
| 58 | Comparison of three zinc binding groups for HDAC inhibitors â€“ A potency, selectivity and enzymatic kinetics study. Bioorganic and Medicinal Chemistry Letters, 2022, 70, 128797. | 1.0 | 10 |
| 59 | Design, synthesis and preliminary biological evaluation of 4-aminopyrazole derivatives as novel and potent JAKs inhibitors. Bioorganic and Medicinal Chemistry, 2016, 24, 2660-2672. | 1.4 | 8 |
| 60 | Novel-targeted therapy for hematological malignancies with JAK and HDAC dual inhibitors. Future Medicinal Chemistry, 2019, 11, 1849-1852. | 1.1 | 8 |
| 61 | Design, synthesis and biological evaluation of dual HDAC and VEGFR inhibitors as multitargeted anticancer agents. Investigational New Drugs, 2022, 40, 10-20. | 1.2 | 8 |
| 62 | Applications and Modifications of 1,2,3,4-Tetrahydroisoquinoline-3-Carboxylic Acid (Tic) in Peptides and Peptidomimetics Design and Discovery. Current Protein and Peptide Science, 2010, 11, 752-758. | 0.7 | 7 |
| 63 | Leucine ureido derivatives as aminopeptidase N inhibitors using click chemistry. Part II. Bioorganic and Medicinal Chemistry, 2019, 27, 978-990. | 1.4 | 7 |
| 64 | Discovery of Multi-target Anticancer Agents Based on HDAC Inhibitor MS-275 and 5-FU. Medicinal Chemistry, 2016, 12, 30-36. | 0.7 | 6 |
| 65 | Design, synthesis, and biological characterization of tamibarotene analogs as anticancer agents. Chemical Biology and Drug Design, 2016, 88, 542-555. | 1.5 | 6 |
| 66 | Inhibitors of the GTPase KRAS<sup>G12C</sup>in cancer: a patent review (2019-2021). Expert Opinion on Therapeutic Patents, 2022, 32, 475-505. | 2.4 | 6 |
| 67 | Design and Synthesis of a Tetrahydroisoquinolineâ€Based Hydroxamate Derivative (<scp>ZYJ</scp>â€34v), An Oral Active Histone Deacetylase Inhibitor with Potent Antitumor Activity. Chemical Biology and Drug Design, 2013, 82, 125-130. | 1.5 | 5 |
| 68 | Discovery of a series of novel compounds with moderate anti-hepatitis C virus NS3 protease activity in vitro. Bioorganic and Medicinal Chemistry, 2015, 23, 5539-5545. | 1.4 | 5 |
| 69 | Synthesis of chiral ND-322, ND-364 and ND-364 derivatives as selective inhibitors of human gelatinase. Bioorganic and Medicinal Chemistry, 2015, 23, 6632-6640. | 1.4 | 5 |
| 70 | Setup Error Assessment and Correction in Planar kV Image- Versus Cone Beam CT Image-Guided Radiation Therapy: A Clinical Study of Early Breast Cancer Treated With External Beam Partial Breast Irradiation. Technology in Cancer Research and Treatment, 2019, 18, 153303381985384. | 0.8 | 5 |
| 71 | <scp>PXD</scp>101 analogs with Lâ€phenylglycineâ€containing branched cap as histone deacetylase inhibitors. Chemical Biology and Drug Design, 2016, 88, 574-584. | 1.5 | 4 |
| 72 | Discovery of a tetrahydroisoquinoline-based HDAC inhibitor with improved plasma stability. Bioorganic and Medicinal Chemistry, 2017, 25, 4614-4619. | 1.4 | 4 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Postmastectomy radiotherapy using three different techniques: a retrospective evaluation of the incidental dose distribution in the internal mammary nodes . Cancer Management and Research, 2019, Volume 11, 1097-1106. | 0.9 | 4 |
| 74 | Development of peptidomimetic hydroxamates as PfA-M1 and PfA-M17 dual inhibitors: Biological evaluation and structural characterization by cocrystallization. Chinese Chemical Letters, 2022, 33, 2550-2554. | 4.8 | 4 |
| 75 | Superior activity of a new histone deacetylase inhibitor (ZYJ-34c) in inhibiting growth of human leukemia cells by inducing p21 WAF1 expression and cell cycle arrest. Anti-Cancer Drugs, 2014, 25, 767-777. | 0.7 | 3 |
| 76 | 3D QSAR and docking studies of a series of histone deacetylase inhibitors. Medicinal Chemistry Research, 2014, 23, 2229-2241. | 1.1 | 3 |
| 77 | Design, synthesis, and antitumor evaluation of histone deacetylase inhibitors with L-phenylglycine scaffold. Drug Design, Development and Therapy, 2015, 9, 5553. | 2.0 | 3 |
| 78 | Clinical investigation into the initial diagnosis and treatment of 539 patients with stage IV lung cancer. OncoTargets and Therapy, 2017, Volume 10, 535-541. | 1.0 | 3 |
| 79 | Synthesis and biological study of class I selective HDAC inhibitors with NO releasing activity. Bioorganic Chemistry, 2020, 104, 104235. | 2.0 | 3 |
| 80 | In vivo pharmacokinetic study and oral glucose tolerance test of sulfoxide analogs of GPR40 agonist TAK â€875. Drug Development Research, 2020, 81, 708-715. | 1.4 | 3 |
| 81 | Comparison of the Gross Target Volumes Based on Diagnostic PET/CT for Primary Esophageal Cancer. Frontiers in Oncology, 2021, 11, 550100. | 1.3 | 3 |
| 82 | Design, synthesis and biological evaluation of hybrid of ubenimex-fluorouracil for hepatocellular carcinoma therapy. Bioorganic Chemistry, 2021, 116, 105343. | 2.0 | 3 |
| 83 | Discovery of a pair of diastereomers as potent HDACs inhibitors: determination of absolute configuration, biological activity comparison and computational study. RSC Advances, 2013, 3, 21106. | 1.7 | 2 |
| 84 | Role of thyroglobulin in the management of patients with differentiated thyroid cancer. Clinical and Translational Imaging, 2019, 7, 209-217. | 1.1 | 2 |
| 85 | Correlation Between Lung Density Changes Under Different Dose Gradients and Radiation Pneumonitisâ€"Based on an Analysis of Computed Tomography Scans During Esophageal Cancer Radiotherapy. Frontiers in Oncology, 2021, 11, 650764. | 1.3 | 2 |
| 86 | Development of pyrazoline-based derivatives as aminopeptidase N inhibitors to overcome cancer invasion and metastasis. RSC Advances, 2021, 11, 21426-21432. | 1.7 | 2 |
| 87 | Design, Synthesis, and Biological Evaluation of APN and AKT Dual-Target Inhibitors. ACS Medicinal Chemistry Letters, 2021, 12, 1932-1941. | 1.3 | 2 |
| 88 | Comparison of planning target volumes based on three-dimensional and four-dimensional CT imaging of thoracic esophageal cancer. OncoTargets and Therapy, 2016, Volume 9, 4785-4791. | 1.0 | 1 |
| 89 | Sulfoxide Analogs of TAK-875 as G Protein Coupled Receptor 40 Agonists: Synthesis, Determination of Absolute Configuration and Biological Activity. Chinese Journal of Organic Chemistry, 2017, 37, 858. | 0.6 | 1 |
| 90 | Letter to the editor: Is it reasonable to prescribe RAI for all DTC patients with a primary tumor diameter exceeding 1Âcm?. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2505-2506. | 3.3 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | Design, Synthesis and Biological Evaluation of Novel Tamibarotene Derivative as Multitarget Anticancer Agent. Letters in Drug Design and Discovery, 2016, 13, 729-733. | 0.4 | 0 |
| 92 | Comparison of biological target volume metrics based on FDG PET-CT and 4DCT for primary non-small-cell lung cancer. Oncotarget, 2017, 8, 79629-79635. | 0.8 | 0 |